NUC-B
Trial Details
- Trial statusRecruiting
- Study email contactnucbtrial@imperial.ac.uk
- Chief InvestigatorProf Mark Thursz
- Project managerMariam Habib
- SponsorImperial College London
- ISRCTN numberISRCTN84346215
- PhaseII
- View Trial Locations
Nucleos(t)ide withdrawal in HBeAg negative hepatitis B virus infection to promote HBsAg clearance
Design and Objective
NUC-B will be a multicentre, randomised, open label trial comparing two management strategies to promote HBsAg loss in patients with HBeAg negative chronic HBV infection.
Key inclusion criteria
• Age ≥ 18 • Chronic HBV infection • HBeAg negative • Nucleos(t)ide analogues treatment for ≥3 years • HBV DNA < 400 IU/ml ≥2 years • Informed consent